Prophylactic strategies to control chikungunya virus infection

Virus Genes. 2021 Apr;57(2):133-150. doi: 10.1007/s11262-020-01820-x. Epub 2021 Feb 15.

Abstract

Chikungunya virus (CHIKV) is a (re)emerging arbovirus and the causative agent of chikungunya fever. In recent years, CHIKV was responsible for a series of outbreaks, some of which had serious economic and public health impacts in the affected regions. So far, no CHIKV-specific antiviral therapy or vaccine has been approved. This review gives a brief summary on CHIKV epidemiology, spread, infection and diagnosis. It furthermore deals with the strategies against emerging diseases, drug development and the possibilities of testing antivirals against CHIKV in vitro and in vivo. With our review, we hope to provide the latest information on CHIKV, disease manifestation, as well as on the current state of CHIKV vaccine development and post-exposure therapy.

Keywords: Antiviral design; Antiviral testing; CHIKV epidemiology; Monoclonal antibodies; Vaccines.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use*
  • Chikungunya Fever / diagnosis
  • Chikungunya Fever / epidemiology
  • Chikungunya Fever / prevention & control*
  • Chikungunya virus / physiology
  • Drug Development
  • Humans
  • Pre-Exposure Prophylaxis*
  • Viral Vaccines

Substances

  • Antiviral Agents
  • Viral Vaccines